NEW YORK — Avellino Labs said today that its Menlo Park, California facility has received CLIA certification, enabling the company to receive and process samples for its AvaGen test for keratoconus and corneal dystrophies.
AvaGen is a next-generation sequencing-based test designed to analyze 1,000 variants across 75 genes to determine the risk of keratoconus, as well as over 70 TGFBI mutations of the transforming growth factor beta induced — or TGFBI — gene for detecting the presence of corneal dystrophies.
With the CLIA certification, Silicon Valley-based Avellino said it plans to being a limited rollout of AvaGen this quarter, with nationwide availability expected in 2020.